Showing results (1-10 of 84) with videos related to

Sort By:
Pageof 9
The Oncologist|March 2, 2019
Retrospect and Prospect for Lung Cancer in China: Clinical Advances of Immune Checkpoint InhibitorsShun Lu, Yongfeng Yu, Yi Yang
Science China. Life Sciences|April 19, 2020
Effectiveness of PD-1/PD-L1 inhibitors in the treatment of lung cancer: Brightness and challengeYing Yang, Yongfeng Yu, Shun Lu
Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer|April 25, 2019
[Treatment-related Skin Toxicity Caused by Programmed Death-1 Inhibitor Nivolumab: 
A Case Report]Lin Gao, Yongfeng Yu, Shun Lu
Medical Oncology (Northwood, London, England)|December 1, 2010
Third-line therapy for advanced non-small-cell lung cancer patients: feasible drugs for feasible patientsZhengbo Song, Yongfeng Yu, Zhiwei Chen, et al.
Cancer Medicine|April 18, 2026
FGFR1 Promotes Malignant Progression in Lung Squamous Cell Carcinoma Through Activation of Wnt/β-Catenin SignalingXingyuan Li, Shuya Mu, Yinjia Sun, et al.
Plos One|October 24, 2018
Cost-effectiveness of ALK testing and first-line crizotinib therapy for non-small-cell lung cancer in ChinaShun Lu, Yongfeng Yu, Shijun Fu, et al.
Journal of Thoracic Disease|November 19, 2019
Prognostic significance of anaplastic lymphoma kinase rearrangement in patients with completely resected lung adenocarcinomaYinglei Liu, Xiangyun Ye, Yongfeng Yu, et al.
Oncotarget|September 9, 2017
Efficacy of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) in targeted therapy of lung squamous cell carcinoma patients with EGFR mutation: a pooled analysisJingqi Zhuang, Yongfeng Yu, Ziming Li, et al.
Journal of Clinical Medicine|June 10, 2022
Comparison of Efficacy and Safety of Brigatinib in First-Line Treatments for Patients with Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Systematic Review and Indirect Treatment ComparisonYongfeng Yu, Fanfan Zhu, Wenxin Zhang, et al.
Annals of Translational Medicine|February 11, 2021
Standardization of pleural effusion-based tumor mutation burden (TMB) estimation using capture-based targeted sequencingYongfeng Yu, Lan Shen, Wenxiang Ji, et al.
Pageof 9